LDN Q&A - 4/18/2026 FB Live
1. LDN is a Tool — Not a Cure-All
LDN can be highly beneficial, especially for immune modulation, but it is not sufficient as a standalone therapy in most complex chronic illnesses. It should be viewed as a cornerstone, not the entire structure.
2. Individual Variability is the Rule
Patient responses to LDN vary widely:
- Some improve dramatically
- Some worsen
- Some require ultra-low doses (microgram/nanogram range)
There is no universal dosing strategy—treatment must be individualized.
3. Dose Sensitivity Reflects Underlying Physiology
Highly sensitive patients (e.g., those with MCAS or severe immune dysregulation) often require:
- Lower starting doses
- Slower titration
This sensitivity may reflect underlying immune instability or endorphin depletion.
4. Endorphin Deficiency as a Clinical Concept
There is a recurring observation of low endorphin reserve in modern patients, potentially due to:
- Chronic stress
- Inflammation
- Environmental factors
However, measurement is difficult and not clinically standardized.
5. MCAS is Increasing and Underrecognized
Mast Cell Activation Syndrome (MCAS) appears to be:
- Increasing in prevalence
- Frequently missed or dismissed
Many complex patients (Lyme, long COVID, chronic fatigue) may have overlapping MCAS physiology.
6. Immune Dysregulation is Central
Conditions discussed (Lyme, long COVID, CFS, MCAS) share:
- Immune dysfunction
- Inflammatory instability
LDN may help regulate—but not fully correct—this dysfunction.
7. Complexity Requires a Systems Approach
Chronic illness management requires:
- Multifactorial treatment
- Functional medicine tools
- Avoiding “single-intervention thinking”
Trying too many therapies at once reduces clarity on cause and effect.
8. Timing and Side Effects Matter
LDN considerations:
- Half-life ~4 hours → timing affects sleep
- Common side effects: insomnia, vivid dreams
- Adjust dosing time (morning vs evening) based on symptoms
9. Sleep is Foundational
Sleep disturbances are common and may be due to:
- MCAS
- Nervous system dysregulation
- Medication effects
Behavioral interventions (e.g., physical activity) remain important.
10. Chronic Infections Are Often Managed, Not Cured
Diseases like Lyme:
- May not be fully eradicated
- Require immune control strategies
LDN may assist, but outcomes are variable.
11. Polypharmacy Obscures Insight
Taking many treatments simultaneously:
- Makes it hard to identify what works
- Increases risk of adverse interactions
Simplicity improves clinical clarity.
12. Evidence Gaps Exist
There is limited high-quality evidence for:
- LDN effects on cholesterol
- Long-term physiologic markers (e.g., HRV)
Clinical observations are valuable but not definitive evidence.
13. Modern Patients Are “Sicker” and Less Resilient
Observed trends:
- Increased stress
- Greater immune dysregulation
- Reduced physiological resilience
This impacts treatment response and recovery.
14. Patient Experience is Valid (Even Without Labs)
Conditions like fibromyalgia highlight:
- Not everything measurable defines reality
- Patient-reported symptoms remain critical
Clinical care must avoid dismissiveness or “gaslighting.”
15. Practical Constraints Affect Care
Real-world factors:
- Cost (compounding, testing)
- Platform rules (e.g., social media restrictions)
- Access to knowledgeable providers
These shape how care is delivered.
